

Bupropion: a systematic review and meta-analysis of ef

Therapeutic Advances in Psychopharmacology

6, 99-144

DOI: [10.1177/2045125316629071](https://doi.org/10.1177/2045125316629071)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bupropion Augmentation in a Case of Compulsive Buying Disorder. <i>Clinical Neuropharmacology</i> , 2017, 40, 189-191.	0.2	3
2	In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. <i>Biochemical Pharmacology</i> , 2017, 123, 85-96.	2.0	28
3	Coma with Absent Brainstem Reflexes and Burst Suppression after Bupropion Overdose in a Child. <i>Neurocritical Care</i> , 2017, 26, 119-121.	1.2	5
4	Preclinical Models for Assessment of Antidepressant Abuse Potential. <i>Current Sexual Health Reports</i> , 2017, 9, 241-250.	0.4	0
5	Depression in Parkinson's Disease: The Contribution from Animal Studies. <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	0.6	13
6	The Brainstem in Emotion: A Review. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 15.	0.9	141
7	Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity. <i>Neural Plasticity</i> , 2017, 2017, 1-18.	1.0	58
8	Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management. <i>Psychiatric Annals</i> , 2017, 47, 154-160.	0.1	15
9	Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion. <i>Obesity Science and Practice</i> , 2018, 4, 141-152.	1.0	23
10	Antidepressants in people with epilepsy: A double-edge sword!. <i>Epilepsy and Behavior</i> , 2018, 79, 247-248.	0.9	3
11	SSRI-associated bruxism. <i>Neurology: Clinical Practice</i> , 2018, 8, 135-141.	0.8	43
12	Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 164, 40-49.	1.3	14
13	Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2133-2165.	2.9	31
14	The effect of bupropion on sexual function in patients with Schizophrenia: A randomized clinical trial. <i>European Journal of Psychiatry</i> , 2018, 32, 11-15.	0.7	5
15	Antidepressant use and the components of the frailty syndrome. <i>Revista Brasileira De Geriatria E Gerontologia</i> , 2018, 21, 7-15.	0.1	3
16	New psychoactive substances—Synthetic stimulants. <i>Wiley Interdisciplinary Reviews Forensic Science</i> , 2019, 1, .	1.2	12
17	Toxicity effects of a novel potent triple reuptake inhibitor, LPM570065, on the fertility and early embryonic development in Sprague-Dawley rats. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 100, 45-51.	1.3	11
19	Pharmacological management of depression in patients with multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1533-1540.	0.9	13

#	ARTICLE	IF	CITATIONS
20	Pharmacosexology: Psychiatric Side Effects of Drugs for the Treatment of Sexual Dysfunction. Trends in Andrology and Sexual Medicine, 2018, , 225-249.	0.1	0
23	Bupropion promotes alterations in the spermatogenesis of mice and congenital malformations in the offspring. Reproduction, Fertility and Development, 2018, 30, 1751.	0.1	2
24	Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders. Bipolar Disorders, 2018, 20, 761-771.	1.1	6
25	Bupropion increases activation in nucleus accumbens during anticipation of monetary reward. Psychopharmacology, 2019, 236, 3655-3665.	1.5	18
26	Neuropsychopharmacological profile of Astragalus membranaceus var. mongholicus. Journal of Traditional Chinese Medical Sciences, 2019, 6, 254-262.	0.1	3
27	Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and) Tj ETQq1 1 0.784314rgBT /Overlock 10		
28	Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metabolism Reviews, 2019, 51, 293-313.	1.5	51
29	Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia. Drugs and Aging, 2019, 36, 589-605.	1.3	24
30	Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial. Clinical Pharmacology and Therapeutics, 2019, 105, 1164-1174.	2.3	10
31	Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease. Pharmaceuticals, 2020, 13, 242.	1.7	29
32	Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults. Clinical Pharmacology and Therapeutics, 2020, 108, 1036-1048.	2.3	2
33	The association of COMT genotype with bupropion treatment response in the treatment of major depressive disorder. Brain and Behavior, 2020, 10, e01692.	1.0	2
34	Antenatal exposure to antidepressant drugs and the risk of neurodevelopmental and psychiatric disorders: a systematic review. Cadernos De Saude Publica, 2020, 36, e00026619.	0.4	6
35	Smokers with insomnia symptoms are less likely to stop smoking. Respiratory Medicine, 2020, 170, 106069.	1.3	4
36	A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093830.	1.4	55
37	Real-world patient experience with sexual dysfunction and antidepressant use in patients with self-reported depression: A cross-sectional survey study. Neurology Psychiatry and Brain Research, 2020, 36, 57-64.	2.0	9
38	The synthesis of novel type of β -aminoketones containing allomaltol fragment. Synthetic Communications, 2021, 51, 701-708.	1.1	4
39	Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder. Pharmacology Biochemistry and Behavior, 2021, 200, 173073.	1.3	6

#	ARTICLE	IF	CITATIONS
40	Treatment resistant depression. , 2021, , 33-84.		0
41	Bupropion-induced acute dystonia in a patient with bulimia nervosa: A case report. Journal of Family Medicine and Primary Care, 2021, 10, 1034.	0.3	2
42	Adverse Effects of Drugs. , 2021, , 295-310.		0
43	The use of sequential pharmacotherapy for the treatment of acute major depression: a scoping review. Expert Opinion on Pharmacotherapy, 2021, 22, 1005-1014.	0.9	1
44	Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression. Journal of Clinical Psychopharmacology, 2021, 41, 281-285.	0.7	8
45	Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response. Translational Psychiatry, 2021, 11, 201.	2.4	5
46	Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures. Polymers, 2021, 13, 1456.	2.0	1
47	Bupropion increases cerebral activation in auditory affective processing: A randomized controlled fMRI study. Neuroscience Letters, 2021, 749, 135716.	1.0	5
48	A Scientometrics Analysis and Visualization of Depressive Disorder. Current Neuropharmacology, 2021, 19, 766-786.	1.4	54
49	Antidepressants' effects on testosterone and estrogens: What do we know?. European Journal of Pharmacology, 2021, 899, 173998.	1.7	33
50	Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight. Journal of Affective Disorders, 2021, 289, 167-176.	2.0	9
51	Visualizing Patterns of Medication Switching Among Major Depressive Patients with Various Stability and Difficulty to Treatments. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1953-1963.	1.0	1
52	Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3. Inflammopharmacology, 2021, 29, 1101-1109.	1.9	1
53	Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. Pharmacological Reviews, 2021, 73, 1084-1117.	7.1	36
54	The current state of tobacco cessation treatment. Cleveland Clinic Journal of Medicine, 2021, 88, 393-404.	0.6	20
55	2-Phenyl-3-(phenylselanyl)benzofuran elicits acute antidepressant-like action in male Swiss mice mediated by modulation of the dopaminergic system and reveals therapeutic efficacy in both sexes. Psychopharmacology, 2021, 238, 3013-3024.	1.5	10
56	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2441-2449.	1.0	0
57	Key considerations in the pharmacological management of treatment-resistant depression. Expert Opinion on Pharmacotherapy, 2021, 22, 2405-2415.	0.9	3

#	ARTICLE	IF	CITATIONS
58	Sexual function in patients with CKD and ESRD. , 2021, , 257-288.		0
59	Bifunctional C2-symmetric ionic liquid-supported (S)-proline as a recyclable organocatalyst for Mannich reactions in neat condition. Results in Chemistry, 2021, 3, 100152.	0.9	5
60	Predicting Response to the Antidepressant Bupropion Using Pretreatment fMRI. Lecture Notes in Computer Science, 2019, 11843, 53-62.	1.0	17
61	Optimized Treatment Strategy for Depressive Disorder. Advances in Experimental Medicine and Biology, 2019, 1180, 201-217.	0.8	14
62	The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative. Menopause, 2020, 27, 1117-1125.	0.8	9
63	Probable Bupropion-Related QTc Prolongation in an Adolescent With Major Depressive Disorder. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	3
65	Differential Treatment Benefit Prediction for Treatment Selection in Depression: A Deep Learning Analysis of STAR*D and CO-MED Data. Computational Psychiatry, 2020, 4, 61.	1.1	14
66	Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1547-1551.	0.5	11
67	Sex enhancers: challenges, threats and the need for targeted measures. Clinica Terapeutica, 2019, 170, e181-e183.	0.2	5
68	Erythrodermic Psoriasis Exacerbated by Bupropion. Cureus, 2021, 13, e18460.	0.2	2
69	Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment, 2021, 25, 1-224.	1.3	62
70	Selective Serotonin Reuptake Inhibitors (SSRIs) and Weight Gain. , 2019, , 55-60.		0
71	Neurophysiological and Neurobiological Basis of Emotions and Mood. Advances in Psychology, Mental Health, and Behavioral Studies, 2019, , 73-89.	0.1	0
72	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
74	Comparative Effectiveness of Antidepressant Medication versus Psychological Intervention on Depression Symptoms in Women with Infertility and Sexual Dysfunction. International Journal of Fertility & Sterility, 2018, 12, 6-12.	0.2	6
75	Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia. Personalized Psychiatry and Neurology, 2021, 1, 21-45.	0.2	2
76	Psychotropic Medications in Metabolic and Bariatric Surgery: Research Updates and Clinical Considerations. Current Psychiatry Reports, 2022, 24, 89-98.	2.1	10
77	Understanding the stimulus effects of nicotine and bupropion in a drug-drug discriminated goal-tracking task. Psychopharmacology, 2022, 239, 819-830.	1.5	1

#	ARTICLE	IF	CITATIONS
78	Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder. <i>Annals of General Psychiatry</i> , 2022, 35, e100724.	1.1	19
79	Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. <i>American Journal on Addictions</i> , 2022, , .	1.3	0
80	Antiretrovirals and Psychotropics: Drug Interactions and Complications. , 2022, , 415-476.		0
81	Isobolographic analysis of the antidepressant interaction in two-drug combinations of citalopram, bupropion, and scopolamine in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 827-837.	1.4	1
83	Weight-centric treatment of depression and chronic pain. , 2022, 3, 100025.		7
84	Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2022, 27, 3658-3669.	4.1	12
85	Uncovering Functional Contributions of PMAT (Slc29a4) to Monoamine Clearance Using Pharmacobehavioral Tools. <i>Cells</i> , 2022, 11, 1874.	1.8	5
86	Pharmacological interventions for Problematic Usage of the Internet (PUI): a narrative review of current progress and future directions. <i>Current Opinion in Behavioral Sciences</i> , 2022, 46, 101158.	2.0	6
87	Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2023, 37, 268-278.	2.0	16
88	Bipolar depression: a review of treatment options. <i>Annals of General Psychiatry</i> , 2022, 35, e100760.	1.1	18
89	Major Depressive Disorder and Depressive Symptoms. , 2022, , 51-59.		0
90	Bupropion - an antidepressant drug with broad therapeutic potential. <i>Journal of Education, Health and Sport</i> , 2022, 12, 591-598.	0.0	1
92	3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
93	Microalgae extract induces antidepressant-like activity via neuroinflammation regulation and enhances the neurotransmitter system. <i>Food and Chemical Toxicology</i> , 2022, 170, 113508.	1.8	4
94	Bupropion and Depressions. , 2022, , 1271-1280.		0
95	Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15114.	1.8	17
96	Depression Pathophysiology: Astrocyte Mitochondrial Melatonergic Pathway as Crucial Hub. <i>International Journal of Molecular Sciences</i> , 2023, 24, 350.	1.8	7
97	Therapy Strategies for Late-life Depression: A Review. <i>Journal of Psychiatric Practice</i> , 2023, 29, 15-30.	0.3	2

#	ARTICLE	IF	CITATIONS
98	Patterns and predictors of antidepressant prescribing among adults with cancer and depression in ambulatory care settings in the United States. <i>Journal of Oncology Pharmacy Practice</i> , 2024, 30, 112-119.	0.5	0
99	Pharmacotherapy in Tobacco Cessation: A Narrative Review. <i>Cureus</i> , 2023, , .	0.2	2
100	Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression. <i>Postgraduate Medicine</i> , 2023, 135, 449-465.	0.9	0
101	Discovery and Development of Monoamine Transporter Ligands. <i>Advances in Neurobiology</i> , 2023, , 101-129.	1.3	1